Lymphoid-derived conventional dendritic cells (L-cDCs) may play a unique function associated with immune suppression and ...

Combining duvelisib and romidepsin may provide a path to stem cell transplant for patients with relapsed or refractory peripheral and cutaneous T-cell lymphomas.  Researchers from Somerville, ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

Like its Big Pharma peers, Cullinan Therapeutics is turning to China for novel drug candidates. The company on Wednesday inked a licensing deal with Genrix Bio, gaining global rights to the ...

In vitro TRAP activity was investigated using RANKL-stimulated RAW264.7 cells. The amount of nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATc1) protein was measured by ...

Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases of NSCLC.. If you have the appropriate software installed, you can download article ...

A study led by Samer Srour, MB, ChB, MS, focuses on AIC100, a novel third-generation CAR T-cell therapy specifically engineered to target ICAM-1 (Intercellular Adhesion Molecule-1), a protein ...

In this study, we demonstrate that CXXC-finger protein 1 (CXXC1) interacts with the transcription factor FOXP3 and facilitates the regulation of target genes by modulating H3K4me3 deposition. Cxxc1 ...

This study presents important findings on the role of CXXC-finger protein 1 in regulatory T cell gene regulation and function. The evidence supporting the authors' claims is convincing, with mostly ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel (cil ...